Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study. J of Skin. 2020;4(1):S2. Accessed October 13, 2025. https://skin.dermsquared.com/skin/article/view/801